YH29143 / Yuhan Corp - LARVOL DELTA

rhIL-7-hyFc (efineptakin alpha; NT-I7) enhances the anti-tumor response when combined with anti-TIGIT or anti-VEGF (AACR 2022) - "Here, we investigated the anti-tumor effect of NT-I7 in combination with two different T cell suppressor blockades; anti-TIGIT (YH29143) and anti-VEGF (Aflibercept) in MC38 tumor-bearing mice. In addition, Aflibercept reduced the expression of TOX in PD-1+ CD8+ T cells in the tumor. Our data suggests that NT-I7 can be applied in combination with other immunotherapies such as anti-TIGIT or anti-VEGF to enhance the anti-tumor response."

IO biomarker • Oncology • CD44 • CD8 • ENTPD1 • IL7 • PD-1 • TIGIT